New Phase II data presented at ENDO 2025 highlight avexitide’s potential to significantly reduce severe hypoglycemic events ...

A new global report finds that clinical research teams are making progress but still lack the skills and tools needed to keep ...

Results from a retrospective study found that Amtagvi (lifileucel) achieved a 48.8% objective response rate in patients with ...

In this video interview, Ramita Tandon, chief biopharma officer at Walgreens, discusses the operational investments required ...